Genzyme treatment aims at reducing costs
Genzyme Corp. in Cambridge released a study showing its Synvisc drug for the treatment of osteoarthritis in the knee has the potential to reduce the cost of treatment to patients.
Through a 26 week trial, Genzyme administered Synvisc in a single dose instead of the typical three-dose regimen in an effort to reduce the total cost to users. Patients using the single dose of Synvisc achieved statistically significant improvements in pain from osteoarthritis compared to those treated with placebo.
253 patients at 21 sites in Europe participated in the study. Both patients and physicians were blinded in the trial, meaning that they were unaware of whether placebo or Synvisc has been administered.
Said Ann Merrifield, president of the Genzyme Biosurgery division: "We believe that delivering the benefits of Synvisc through one administration rather than three will provide additional options for physicians and patients that will reduce the cost and burden of multiple injections."
Genzyme Corp. has operations in Westboro.
WBJ Web Partners
Most Recent
Most Recent
0 Comments